CAR T-cell Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL): UChicago Medicine

 

The FDA recently approved a breakthrough gene therapy treatment for pediatric acute lymphoblastic leukemia (ALL),called Chimeric Antigen Receptor T-cell (CAR T-cell) therapy. CAR T-cell therapy uses modified versions of a patient’s own blood cells to target and destroy cancer cells.

UChicago Medicine is among the first healthcare sites in the U.S. to be certified to offer CAR T-cell therapy. If you have a patient up to 25 years of age with acute lymphoblastic leukemia that is refractory or in second or later relapse who may be a candidate for this treatment option, or would like to learn more, please don’t hesitate to contact our CAR T-cell therapy team 24/7 at 844-482-7823.

Admissions, Referrals and Consultations:

Call UCM Physician Connect at
1-800-824-2282
Contact Us